Key result
A high dose (4.9 g per 70 kg) of long-chain n-3 polyunsaturated fatty acids significantly improved postprandial flow-mediated dilatation compared with a saturated fat meal.
Why the study?
Does dietary long-chain n-3 polyunsaturated fatty acid (EPA and DHA) improve vascular function measured by flow-mediated dilatation in healthy and diseased individuals?
Does dietary long-chain n-3 polyunsaturated fatty acid (EPA and DHA) improve vascular function measured by flow-mediated dilatation in healthy and diseased individuals?
High-dose acute intake of EPA/DHA improves postprandial vascular function in healthy individuals, but evidence for long-term benefits in diseased populations remains limited.
Acute high-dose n-3 PUFA may support postprandial endothelial benefits in healthy subjects; leaves open long-term effects in cardiovascular disease.
PURPOSE OF REVIEW: Vascular function is recognized as an early and integrative marker of cardiovascular disease. While there is consistent evidence that the quantity of dietary fat has significant effects on vascular function, the differential effects of individual fatty acids is less clear. This review summarizes recent evidence from randomly controlled dietary studies on the impact of dietary fatty acids on vascular function, as determined by flow-mediated dilatation (FMD). RECENT FINDINGS: Critical appraisal is given to five intervention studies (one acute, four chronic) which examined the impact of long-chain n-3 polyunsaturated fatty acid [eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)] on FMD. In the acute setting, a high dose of long-chain n-3 polyunsaturated fatty acid (4.9 g per 70 kg man) improved postprandial FMD significantly, compared with a saturated fatty acid-rich meal in healthy individuals. In longer-term studies, there was limited evidence for a significant effect of EPA/DHA on FMD in diseased groups. SUMMARY: The strongest evidence for the benefits of EPA/DHA on vascular function is in the postprandial state. More evidence from randomly controlled intervention trials with foods will be required to substantiate the long-term effects of EPA/DHA, to inform public health and clinical recommendations.
No takes yet. Share an insight, caveat, or question.
Lovegrove et al. (2013) conducted a review in Vascular function in health and disease. Long-chain n-3 polyunsaturated fatty acids (EPA and DHA) vs. Saturated fatty acid-rich meal was evaluated on Vascular function as determined by flow-mediated dilatation (FMD). A high dose (4.9 g per 70 kg) of long-chain n-3 polyunsaturated fatty acids significantly improved postprandial flow-mediated dilatation compared with a saturated fat meal.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: